Italia markets close in 7 hours 31 minutes

FTSE MIB
34.617,65
-207,36(-0,60%)
Dow Jones
39.806,77
-196,82(-0,49%)
Nasdaq
16.794,88
+108,91(+0,65%)
Nikkei 225
38.946,93
-122,75(-0,31%)
Petrolio
79,25
-0,55(-0,69%)
Bitcoin EUR
65.267,04
+3.724,45(+6,05%)

NBIX May 2024 90.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

0,8500

0,0000

(0,00%)

In data: 01:43PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat